1
artículo
Publicado 2020
Enlace
Enlace
Acetylcholinesterase (AChE) is one of the most well-known biomarkers in ecotoxicological monitoring programs of organophosphates and carbamates. However, some studies suggest that acetylcholinesterase also act as a biomarker for other xenobiotics. With this approach we conducted comparison tests of this biomarker in two locations in the city of Arraial do Cabo – RJ, Brazil. Dos Anjos Beach is a cove that has a port considered as an environment impacted by tributyltin, with the oceanic beach Praia Grande introduced in our study as a reference environment. In two samples (03/04/2004 and 09/06/2005) the specific activities of acetylcholinesterase activity in gills of Pernaperna were higher in Dos Anjos Beach corroborating laboratory experiments conducted by other authors. Additional studies are important for the determination of imposex associated with acetylcholinesterase, and can also i...
2
artículo
Publicado 2021
Enlace
Enlace
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
3
artículo
Publicado 2020
Enlace
Enlace
Introduction and aims Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results The distributi...
4
artículo
Publicado 2020
Enlace
Enlace
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic F...
